Robert E. Gagnon
CIK: 0001504983
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Oct 23, 2026IRD
Opus Genetics, Inc.
Sale(S)Direct14K shares at avg. $3.55$50K - Sep 3, 2026IRD
Opus Genetics, Inc.
Sale(S)Direct28K shares at avg. $4.54$127K - Jul 23, 2026IRD
Opus Genetics, Inc.
Sale(S)Direct7.8K shares at avg. $2.95$23K - Jun 9, 2026HBIO
HARVARD BIOSCIENCE INC
Award(A)Direct16.6K shares- - Apr 23, 2026IRD
Opus Genetics, Inc.
Sale(S)Direct7.8K shares at avg. $5.18$41K - Jan 22, 2026IRD
Opus Genetics, Inc.
Award(A)Direct400K shares- - Dec 16, 2025VSTM
Verastem, Inc.
Sale(S)Direct283 shares at avg. $9.14$3K - Sep 16, 2025VSTM
Verastem, Inc.
Sale(S)Direct281 shares at avg. $9.99$3K - Sep 10, 2025IRD
Opus Genetics, Inc.
Award(A)Direct200K shares- - Sep 2, 2025IRD
Opus Genetics, Inc.
Award(A)DirectEmployee Stock Option (right to buy)
250K shares- - Jul 16, 2025HBIO
HARVARD BIOSCIENCE INC
Award(A)Direct110K shares- - Jun 16, 2025VSTM
Verastem, Inc.
Sale(S)Direct284 shares at avg. $5.65$2K - Jun 4, 2025BBLG
Bone Biologics Corp
Award(A)DirectNon-Employee Stock Option
62.9K shares- - May 22, 2025VSTM
Verastem, Inc.
Award(A)Direct8.3K shares- - Mar 17, 2025VSTM
Verastem, Inc.
Sale(S)Direct284 shares at avg. $6.95$2K - Dec 19, 2024VSTM
Verastem, Inc.
Sale(S)Direct130 shares at avg. $4.37$568.1 - Dec 16, 2024VSTM
Verastem, Inc.
Sale(S)Direct285 shares at avg. $4.54$1K - Sep 19, 2024VSTM
Verastem, Inc.
Sale(S)Direct131 shares at avg. $2.79$365.49 - Sep 17, 2024BBLG
Bone Biologics Corp
Award(A)DirectNon- Employee Stock Option
30.7K shares- - Sep 16, 2024VSTM
Verastem, Inc.
Sale(S)Direct287 shares at avg. $2.80$803.6
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 23, 2026 |  IRD Opus Genetics, Inc. | Sale(S) | 14,000 | $3.55 | $49,650 | Direct |
| Sep 3, 2026 | IRD Opus Genetics, Inc. | Sale(S) | 28,000 | $4.54 | $127,212 | Direct |
| Jul 23, 2026 | IRD Opus Genetics, Inc. | Sale(S) | 7,783 | $2.95 | $22,942 | Direct |
| Jun 9, 2026 |  HBIO HARVARD BIOSCIENCE INC | Award(A) | 16,556 | - | $0 | Direct |
| Apr 23, 2026 | IRD Opus Genetics, Inc. | Sale(S) | 7,842 | $5.18 | $40,658 | Direct |
| Jan 22, 2026 | IRD Opus Genetics, Inc. | Award(A) | 400,000 | - | $0 | Direct |
| Dec 16, 2025 |  VSTM Verastem, Inc. | Sale(S) | 283 | $9.14 | $2,587 | Direct |
| Sep 16, 2025 | VSTM Verastem, Inc. | Sale(S) | 281 | $9.99 | $2,807 | Direct |
| Sep 10, 2025 | IRD Opus Genetics, Inc. | Award(A) | 200,000 | - | - | Direct |
| Sep 2, 2025 | IRD Opus Genetics, Inc. | Award(A) Employee Stock Option (right to buy) | 250,000 | - | - | Direct |
| Jul 16, 2025 | HBIO HARVARD BIOSCIENCE INC | Award(A) | 110,000 | - | - | Direct |
| Jun 16, 2025 | VSTM Verastem, Inc. | Sale(S) | 284 | $5.65 | $1,605 | Direct |
| Jun 4, 2025 |  BBLG Bone Biologics Corp | Award(A) Non-Employee Stock Option | 62,894 | - | - | Direct |
| May 22, 2025 | VSTM Verastem, Inc. | Award(A) | 8,333 | - | - | Direct |
| Mar 17, 2025 | VSTM Verastem, Inc. | Sale(S) | 284 | $6.95 | $1,974 | Direct |
| Dec 19, 2024 | VSTM Verastem, Inc. | Sale(S) | 130 | $4.37 | $568 | Direct |
| Dec 16, 2024 | VSTM Verastem, Inc. | Sale(S) | 285 | $4.54 | $1,294 | Direct |
| Sep 19, 2024 | VSTM Verastem, Inc. | Sale(S) | 131 | $2.79 | $365 | Direct |
| Sep 17, 2024 | BBLG Bone Biologics Corp | Award(A) Non- Employee Stock Option | 30,713 | - | - | Direct |
| Sep 16, 2024 | VSTM Verastem, Inc. | Sale(S) | 287 | $2.80 | $804 | Direct |
1-20 of 20 transactions
About Gagnon Robert E.
Gagnon Robert E. (SEC CIK 0001504983) files insider reports with the SEC as Chief Financial Officer of Opus Genetics, Inc. (IRD), Director of HARVARD BIOSCIENCE INC (HBIO) and Director of PURPLE BIOTECH LTD. (PPBT). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 21 ownership filings by Gagnon Robert E. (3 Form 3, 18 Form 4), filed between Sep 18, 2024 and Oct 27, 2026. Those filings report 20 transactions, from Sep 16, 2024 to Oct 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gagnon Robert E.'s filings is in DURHAM, NC.
Recent filings by Gagnon Robert E.
- Oct 23, 2026: Open-market sale of IRD shares (Form 4, code S).
- Sep 3, 2026: Open-market sale of IRD shares (Form 4, code S).
- Jul 23, 2026: Open-market sale of IRD shares (Form 4, code S).
- Jun 9, 2026: Grant or award of HBIO shares (Form 4, code A).
- Apr 23, 2026: Open-market sale of IRD shares (Form 4, code S).
Other insiders filing for Opus Genetics, Inc. (IRD)
- SCHACHLE JOSEPH K, Chief Operating Officer
- YERXA BENJAMIN R, President
- Magrath George, Chief Executive Officer
- Foundation Fighting Blindness Retinal Degeneration Fund, Director
- Gallagher Cam, Director
- Zaremba Rabourn Amy, Head of Fin. Quality Assurance